Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2017/0137544 METHOD FOR MANUFACTURE OF LOW EMISSIONS POLYPROPYLENE
The present invention relates to a method for the manufacture of polypropylene having a target melt flow rate of from 10 to 200 g/10 min as determined in...
2017/0137543 HYDROFLUOROCARBON RECOVERY METHOD
A method for recovering a hydrofluorocarbon, including: producing a wet fluoropolymer by suspension polymerization, solution polymerization, or bulk...
2017/0137542 METHOD OF MAKING A BRANCHED POLYMER, A BRANCHED POLYMER AND USES OF SUCH A POLYMER
A method of making a branched polymer comprising (C.dbd.C)--(C.dbd.C)--CO groups is provided. The method comprises: (i) Providing, in admixture, at least one...
2017/0137541 METHOD OF PRODUCTION OF MODIFIED CONJUGATED DIENE RUBBER
A method of production of a modified conjugated diene rubber including a first step of polymerizing a monomer containing at least a conjugated diene compound...
2017/0137540 DYE COMPLEX, PHOTOCONVERSION FILM AND ELECTRONIC ELEMENT INCLUDING SAME
The present specification relates to a dye complex, a light conversion film, and an electronic device including the same.
2017/0137539 CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES
Provided are bispecific antibody compounds having the Formula I: ##STR00001## wherein, FAB.sup.1, FAB.sup.2, and --X-- are as defined herein. The provided...
2017/0137538 PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA
The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding...
2017/0137537 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA...
2017/0137536 INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
2017/0137535 ANTI-FACTOR D ANTIBODY FORMULATIONS
Pharmaceutical formulations comprising monoclonal anti-Factor D antibodies, and their production and use for the treatment of complement-associated ocular...
2017/0137534 Anti-Pancreatic Cancer Antibodies
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human...
2017/0137533 ANTI-DLL3 ANTIBODIES AND DRUG CONJUGATES FOR USE IN MELANOMA
Anti-DLL3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.
2017/0137532 TUMOR SELECTIVE MACROPINOCYTOSIS-DEPENDENT RAPIDLY INTERNALIZING ANTIBODIES
Methods are provided for identifying and selecting antibodies that are internalized into cells via the macropinocytosis pathway. Additionally antibodies that...
2017/0137531 ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
The invention provides anti-Jagged1 antibodies and methods of using the same.
2017/0137530 ANTIBODY FC VARIANTS
The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced...
2017/0137529 Therapeutic Antibodies
A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the...
2017/0137528 DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
2017/0137527 GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN IMMUNE RESPONSE
The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of...
2017/0137526 USE OF INTERLEUKIN-4 ANTAGONISTS AND COMPOSITIONS THEREOF
Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition....
2017/0137525 METHODS OF TREATING SKIN DISORDERS USING AN ANTI-IL-31RA ANTIBODY
The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic...
2017/0137524 THERAPIES BASED ON CONTROL OF REGULATORY T CELL STABILITY AND FUNCTION VIA A NEUROPILIN-1:SEMAPHORIN AXIS
The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and...
2017/0137523 THERAPY FOR GIST
The invention provides for the human antibodies that bind to human platelet-derived growth factor receptor alpha (PDGFR alpha), preferably olaratumab, for the...
2017/0137522 TARGETED BINDING AGENTS AGAINST B7-H1
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity...
2017/0137521 CTLA4 BINDERS
The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as...
2017/0137520 PD1/CTLA4 BINDERS
The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been...
2017/0137519 CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3
The present invention relates to CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are ...
2017/0137518 PILR ALPHA INTERACTIONS AND METHODS OF MODIFYING SAME
Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the...
2017/0137517 PD1 and/or LAG3 BINDERS
The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have...
2017/0137516 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at...
2017/0137515 CAR BASED IMMUNOTHERAPY
The disclosure provides chimeric antigen receptors (CARs), T cells comprising such CARs, nucleic acids that encode such CARS, and methods of use thereof, e.g.,...
2017/0137514 OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously...
2017/0137513 METHODS AND COMPOSITIONS FOR BI-SPECIFIC TARGETING OF CD19/CD22
Methods and composition involving genetically engineered targeting conjugates with reversed orientation of V.sub.L and V.sub.H chains are provided. For...
2017/0137512 KV1.3 BINDING IMMUNOGLOBULINS
The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides;...
2017/0137511 ANTIBODIES TO IL-15
The present invention relates to antibodies binding IL-15, in particular humanized antibodies. In particular, the anti-IL-15 antibodies according to the...
2017/0137510 Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor...
2017/0137509 VACCINES AND MONOCLONAL ANTIBODIES TARGETING TRUNCATED VARIANTS OF OSTEOPONTIN AND USES THEREOF
The present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one...
2017/0137508 METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS
This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to...
2017/0137507 TGF- 1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-.beta.1) are provided,...
2017/0137506 TREATMENT OF CHRONIC KIDNEY DISEASE AND OTHER RENAL DYSFUNCTION USING A GDF15 MODULATOR
The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal...
2017/0137505 TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR
The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF),...
2017/0137504 VNAR RECOMBINANT MONOCLONAL ANTIBODIES THAT NEUTRALIZE VASCULAR ENDOPHELIAL GROWTH FACTOR VEGF
The present invention refers to the selection, isolation and purification of proteins belonging to variable regions named V.sub.HNAR or vNAR, originated from...
2017/0137503 ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of...
2017/0137502 PHOSPHOSPECIFIC ANTIBODIES RECOGNISING TAU
The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by...
2017/0137501 Anti-Bed Bug Monoclonal Antibodies and Methods of Making and Uses Thereof
The present disclosure provides anti-bed bug monoclonal antibodies and antigen-binding fragments thereof as well as compositions and kits comprising the same....
2017/0137500 ANTIBODY PURIFICATION AND PURITY MONITORING
Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying...
2017/0137499 INHIBITORS OF C5A FOR THE TREATMENT OF VIRAL PNEUMONIA
The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of...
2017/0137498 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLUENZA
This disclosure relates to peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and...
2017/0137497 IMMUNOGLOBULIN PURIFICATION
The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an...
2017/0137496 METHODS TO CONTROL PROTEIN HETEROGENEITY
The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the ...
2017/0137495 TIMP3 AS VEGF INHIBITOR
Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.